Metoprolol Succinate
Product Images NDC 68071-2455

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 68071-2455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2455 1)

Pdp (68071 2455 1)
Label for Metoprolol Succinate 50mg extended-release tablets by NuCare Pharmaceuticals, Inc. The label shows NDC 68071-2455-1 and indicates each tablet contains 47.5mg metoprolol succinate equivalent to 50mg metoprolol tartrate USP. The label includes directions for patient use, manufacturer information, lot and expiration details, and storage instructions at controlled temperature (68-77°F).*
FDA Label Image

Image (B6d50141 4598 4f04 B407 08df00bf4537 01)

Image (B6d50141 4598 4f04 B407 08df00bf4537 01)
Chemical structure of metoprolol succinate depicting the molecular composition and arrangement of the active ingredient in the product by NuCare Pharmaceuticals, Inc.*
FDA Label Image

Merit Hf (B6d50141 4598 4f04 B407 08df00bf4537 02)

Merit Hf (B6d50141 4598 4f04 B407 08df00bf4537 02)
A forest plot chart titled 'Results for Subgroups in MERIT-HF' comparing relative risk and 95% confidence intervals for metoprolol succinate extended-release tablets versus placebo. It presents data across various subgroups such as geographic location, NYHA class, ejection fraction levels, ischemic etiology, sex, race, myocardial infarction history, diabetes status, hypertension history, and heart rate. The chart includes three panels showing outcomes for total mortality, total mortality or all-cause hospitalization, and total mortality or hospitalization for heart failure, with risk favoring either metoprolol succinate extended-release tablets or placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.